{
    "clinical_study": {
        "@rank": "36884", 
        "arm_group": {
            "arm_group_label": "4-valent HPV vaccine", 
            "arm_group_type": "Experimental", 
            "description": "4-valent HPV vaccine administered in months 0., 2., 6."
        }, 
        "brief_summary": {
            "textblock": "Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life\n      threatening condition resulting in surgical interventions. The maturing and disintegrating\n      papillomas are the sources for the subsequent HPV relapses and immunization might slow down\n      or even prevent this ongoing process.\n\n      After an initial immunological and ear-nose-throat (ENT) assessment children with at least 3\n      relapses in their patient history will be vaccinated with 4-valent HPV vaccine according to\n      the following schedule: 0., 2., 6. months. It will be followed by an immunological and 3 ENT\n      examinations to assess response to vaccination."
        }, 
        "brief_title": "4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Respiratory Papillomatosis", 
        "condition_browse": {
            "mesh_term": [
                "Papilloma", 
                "Respiratory Tract Infections", 
                "Papillomavirus Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Enrollment\n\n             -  ear-nose-throat (ENT) examination + oesophagoscopy\n\n             -  immunological assessment\n\n                  -  assessment of selected humoral (antibodies) and\n\n                  -  cellular immune response parameters(INF gamma and granzyme B testing)\n\n                  -  in vitro and in vivo stimulation of PMBCs with the HPV-4 vaccine\n\n        2. Immunization with 4-valent HPV vaccine at 0,2,6 months\n\n        3. Follow up\n\n             -  1 month after 3rd vaccine dose - immunological assessment (same tests as in the\n                enrollment phase)\n\n             -  6, 12 and 18 months after the 3rd vaccine dose - ENT + oesophagoscopy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  respiratory papillomatosis\n\n          -  at least 3 relapses in patient history\n\n          -  HPV 6 and/or 11 positive papillomas\n\n          -  able to mount neutralizing antibodies\n\n        Exclusion Criteria:\n\n          -  other chronic underlying condition\n\n          -  other HPV type\n\n          -  no antibody response"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995721", 
            "org_study_id": "50934"
        }, 
        "intervention": {
            "arm_group_label": "4-valent HPV vaccine", 
            "description": "Vaccination with 4-valent HPV vaccine in months 0., 2., 6.", 
            "intervention_name": "4-valent HPV vaccine", 
            "intervention_type": "Biological", 
            "other_name": [
                "Silgard", 
                "Gardasil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "recurrent respiratory papillomatosis", 
            "human papillomavirus", 
            "vaccine", 
            "treatment", 
            "immunology", 
            "relapse"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "email": "zmeszner@gmail.com", 
                "last_name": "Zsofia Meszner", 
                "phone": "+36 1 365-1540"
            }, 
            "facility": {
                "address": {
                    "city": "Budapest", 
                    "country": "Hungary", 
                    "zip": "1113"
                }, 
                "name": "National Institute of Child Health"
            }, 
            "investigator": {
                "last_name": "Zsofia Meszner, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Hungary"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children", 
        "overall_contact": {
            "email": "zmeszner@gmail.com", 
            "last_name": "Zsofia Meszner, MD, PhD", 
            "phone": "+36 1 365 1540"
        }, 
        "overall_official": {
            "affiliation": "National Institute of Child Health", 
            "last_name": "Zsofia Meszner, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Hungary: National Institute of Pharmacy", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of relapses and surgical treatment needed after the 3rd vaccine dose during the 18--months follow-up period", 
            "measure": "Papilloma relapses", 
            "safety_issue": "No", 
            "time_frame": "18 months after the 3rd vaccine"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995721"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Institute of Child Health, Hungary", 
            "investigator_full_name": "dr. med habil Zs\u00f3fia Meszner PhD", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "National Institute of Child Health, Hungary", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Child Health, Hungary", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}